Ironwood Pharmaceuticals, Inc: Still A Profitable Opportunity
Ironwood Pharmaceuticals, Inc. is currently rated as a Hold, indicating a potential for upside despite recent challenges. The company reported strong sales for Linzess, which continues to dominate the IBS-C and CIC therapy market. Additionally, the upcoming Phase III trial for apraglutide presents significant growth opportunities for the company.
- ▪Ironwood Pharmaceuticals (IRWD) has a current market price that reflects a discount and potential for upside.
- ▪Linzess generated Q1 FY2026 net sales of $275.5 million, maintaining a ~75% market share in its category.
- ▪The company anticipates FY2026 US Linzess net sales between $1.125 billion and $1.175 billion.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905669-ironwood-pharmaceuticals-inc-still-a-profitable-opportunity"},"author":{"@type":"Person","name":"Andrea De Vico","url":"https://seekingalpha.com/author/andrea-de-vico"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
